The short version of Anti-doping testing fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-28. Anything still debated is marked as such rather than presented as settled.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
=== Democratic primary === Caitlin Rourk, Democratic Nominee for the 10th Congressional District, grew up near Washington, D.C., as the daughter of two public school teachers. She served as an intelligence officer in the Texas Army National Guard and U.S. Army Reserve, participating in full-time missions supporting disaster response, border operations, and public health programs. Early in her career, Rourk engaged in bipartisan public policy work focused on deficit reduction and energy security, later leading corporate communications at Dell Technologies. A resident of Central Texas for over a decade, she lives in the Eanes Independent School District, where her children attend public school. Rourk is the Democratic nominee running to represent Texas's 10th Congressional District in the 2026 election, winning her primary with more than 60% of the vote for an open seat created by the retirement of long-serving Republican Representative Michael McCaul. The newly drawn district encompasses 13 counties, stretching from the Houston suburbs through rural East Texas to northern Austin. Positioning herself as a pragmatic problem solver and servant leader, Rourk has centered her campaign on grassroots door-knocking, deep organizing, and restoring accountability through proposals such as mandating regular open town halls in every congressional district.
Anemia Insufficient red cell mass (anemia) can be the result of bleeding, blood disorders like thalassemia, or nutritional deficiencies, and may require one or more blood transfusions. Anemia can also be due to a genetic disorder in which the red blood cells do not function effectively. Anemia can be confirmed by a blood test if the hemoglobin value is less than 13.5 gm/dl in men or less than 12.0 gm/dl in women. Several countries have blood banks to fill the demand for transfusable blood. A person receiving a blood transfusion must have a blood type compatible with that of the donor. Sickle-cell anemia Disorders of cell proliferation Leukemia is a group of cancers of the blood-forming tissues and cells. Non-cancerous overproduction of red cells (polycythemia vera) or platelets (essential thrombocytosis) may be premalignant. Myelodysplastic syndromes involve ineffective production of one or more cell lines. Disorders of coagulation Hemophilia is a genetic illness that causes dysfunction in one of the blood's clotting mechanisms. This can allow otherwise inconsequential wounds to be life-threatening, but more commonly results in hemarthrosis, or bleeding into joint spaces, which can be crippling. Ineffective or insufficient platelets can also result in coagulopathy (bleeding disorders). Hypercoagulable state (thrombophilia) results from defects in regulation of platelet or clotting factor function, and can cause thrombosis. Infectious disorders of blood Blood is an important vector of infection.
=== Media === In literature, characters believed to exhibit signs of BPD include Catherine in Wuthering Heights (1847), Smerdyakov in The Brothers Karamazov (1880), and Harry Haller in Steppenwolf (1927). Films have also attempted to portray BPD, with characters in Margot at the Wedding (2007), Mr. Nobody (2009), Cracks (2009), Truth (2013), Wounded (2013), Welcome to Me (2014), and Tamasha (2015) all suggested to show traits of the disorder. The behavior of Theresa Dunn in Looking for Mr. Goodbar (1975) is consistent with BPD, as suggested by Robert O. Friedel. Films like Play Misty for Me (1971) and Girl, Interrupted (1999, based on the memoir of the same name) suggest emotional instability characteristic of BPD, while Single White Female (1992) highlights aspects such as identity disturbance and fear of abandonment. Clementine in Eternal Sunshine of the Spotless Mind (2004) is noted to show classic BPD behavior, and Carey Mulligan's portrayal in Shame (2011) is praised by psychiatrists for its accuracy regarding BPD characteristics. Television series like Crazy Ex-Girlfriend (2015) and the miniseries Maniac (2018) depict characters with BPD. Traits of BPD and narcissistic personality disorders are observed in characters like Cersei and Jaime Lannister from A Song of Ice and Fire (1996) and its TV adaptation Game of Thrones (2011). In The Sopranos (1999), Livia Soprano is diagnosed with BPD, and even the portrayal of Bruce Wayne/Batman in the show Titans (2018) is said to include aspects of the disorder.
=== Mechanisms and therapeutics for neurodevelopmental disorders === Sur’s group has applied this understanding of plasticity to study disorders of brain development. Rett Syndrome is a devastating neurodevelopmental disorder caused by mutations in MECP2, a transcriptional regulator. Sur hypothesized that a core mechanism of Rett Syndrome is the persistence of immature synapses which may be induced to mature. Rett model mice indeed have a deficit in PI3K/Akt/Erk signaling and PSD95 expression, leading to immature excitatory synapses and prolonged visual cortex plasticity that extends into adulthood. Application of IGF1(1-3) peptide, which degrades IGF binding proteins produced by astrocytes and enhances IGF1 availability, and of full-length IGF1, upregulates these signals to restore normal synaptic plasticity and function and improve behavioral phenotypes. Human Rett IPSC-derived neurons show deficits in IGF1 and similar effectiveness of IGF1 in restoring PI3K, AKT and S6 signals. Based on the lab’s work, an IGF1(1-3) mimetic – trofinetide - was employed in clinical trials for Rett Syndrome. In 2023, trofinetide was approved by the FDA as the first treatment for Rett Syndrome. This work has played an important part in raising optimism that even major disorders of brain development may be treated effectively when understood mechanistically.
Sources: en.wikipedia.org
{\displaystyle {\begin{array}{ll}{\ce {A^2- + H+ <=> HA-}}:&\beta _{1}={\frac {{\ce {[HA^-]}}}{{\ce {[A^{2-}] [H+]}}}}\\{\ce {A^2- + 2H+ <=> H2A}}:&\beta _{2}={\frac {{\ce {[H2A]}}}{{\ce {[A^{2-}] [H+]^2}}}}\end{array}}}
The U.S. 101st Airborne Division and ARVN 1st Division launch Operation Apache Snow in the A Shau Valley. The operation results in 977 PAVN killed and five captured while U.S. losses were 113 killed and ARVN losses were 31 killed. Most of the U.S. casualties were in the Battle of Hamburger Hill from May 13–20 where U.S. forces attacked heavily fortified PAVN positions on Hill 937. 630 PAVN, 72 U.S. and 31 ARVN were killed in the fighting for Hill 937.
The Aston Medal is awarded by the British Mass Spectrometry Society to individuals who have worked in the United Kingdom and have made outstanding contributions to our understanding of the biological, chemical, engineering, mathematical, medical, or physical sciences relating directly to mass spectrometry. The medal is named after one of Britain's founders of mass spectrometry and 1922 Nobel prize winner Francis William Aston. The award is made sporadically, with no more than one medal being awarded each year. Recipients of this honour receive a gold-plated medal with a portrait of Francis Aston as well as an award certificate.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.